References:
1. Rabiul Islam M, Nasreen W, Anjum R, et al. Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health. Clin Pathol. 2022;15:2632010X221124908
2. Miller IF, Becker AD, Grenfell BT, Metcalf C. Disease and healthcare burden of COVID-19 in the United States. Nat Med. 2020;26(8):1212-1217
3. Suzuki R, Yamasoba D, Kimura I, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. 2022;603(7902):700-705
4. Yuan S, Ye ZW, Liang R, et al. Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. Science. 2022;377(6604):428-433
5. Bálint G, Vörös-Horváth B, Széchenyi A. Omicron: increased transmissibility and decreased pathogenicity. Signal Transduct Target Ther. 2022;7(1):151
6. Grabowski F, Kochańczyk M, Lipniacki T. The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0-3.3 Days Can Be Explained by Immune Evasion. Viruses. 2022;14(2)
7. Vitiello A, Ferrara F, Auti AM, Di Domenico M, Boccellino M. Advances in the Omicron variant development. J Intern Med. 2022;292(1):81-90
8. SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(50):1731-1734
9. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern (WHO, 2021) .
10. Zhang J, Rao X, Li Y, et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. Ann Intensive Care. 2021;11(1):5
11. Sahin G, Akbal-Dagistan O, Culha M, et al. Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment. J Pharm Sci. 2022;111(10):2652-2661
12. Chu D, Pan Y, Cheng S, et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clin Chem. 2020;66(4):549-555
13. Grant RA, Morales-Nebreda L, Markov NS, et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021;590(7847):635-641
14. Zu ZY, Jiang MD, Xu PP, et al. Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology. 2020;296(2):E15-E25
15. Shuai H, Chan JF, Hu B, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature. 2022;603(7902):693-699
16. Lee JE, Hwang M, Kim YH, et al. SARS-CoV-2 Variants Infection in Relationship to Imaging-based Pneumonia and Clinical Outcomes. Radiology. 2023;306(3):e221795
17. Bai HX, Hsieh B, Xiong Z, et al. Performance of Radiologists in Differentiating COVID-19 from Non-COVID-19 Viral Pneumonia at Chest CT. Radiology. 2020;296(2):E46-E54
18. Fields B, Demirjian NL, Dadgar H, Gholamrezanezhad A. Imaging of COVID-19: CT, MRI, and PET. Semin Nucl Med. 2021;51(4):312-320
19. Long C, Xu H, Shen Q, et al. Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT. Eur J Radiol. 2020;126:108961
20. Yang J, Chen X, Deng X, et al. Disease burden and clinical severity of the first pandemic wave of COVID-19 in Wuhan, China. Nat Commun. 2020;11(1):5411
21. Wang X, Wang S, Sun L, Qin G. Prevalence of diabetes mellitus in 2019 novel coronavirus: A meta-analysis. Diabetes Res Clin Pract. 2020;164:108200
22. Hou W, Zhang W, Jin R, Liang L, Xu B, Hu Z. Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study. Infect Dis (Lond). 2020;52(7):498-505
23. Okuyan HM, Dogan S, Bal T, Çabalak M. Beclin-1, an autophagy-related protein, is associated with the disease severity of COVID-19. Life Sci. 2021;278:119596
24. Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob. 2020;19(1):18
25. Hachim MY, Hachim IY, Naeem KB, Hannawi H, Salmi IA, Hannawi S. D-dimer, Troponin, and Urea Level at Presentation With COVID-19 can Predict ICU Admission: A Single Centered Study. Front Med (Lausanne). 2020;7:585003
26. Zingaropoli MA, Nijhawan P, Carraro A, et al. Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia. Front Immunol. 2021;12:627548
27. Jakubzick CV, Randolph GJ, Henson PM. Monocyte differentiation and antigen-presenting functions. Nat Rev Immunol. 2017;17(6):349-362
28. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529-539
29. Chang MC, Park YK, Kim BO, Park D. Risk factors for disease progression in COVID-19 patients. BMC Infect Dis. 2020;20(1):445
30. Terada M, Ohtsu H, Saito S, et al. Risk factors for severity on admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in Japan. BMJ Open. 2021;11(6):e047007
31. Ninomiya T, Otsubo K, Hoshino T, et al. Risk factors for disease progression in Japanese patients with COVID-19 with no or mild symptoms on admission. BMC Infect Dis. 2021;21(1):850